Alessandro Colitta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessandro Colitta has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Ugo Faraguna
Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa , Pisa
7 shared publications - Simone Bruno
Department of Psychiatry, University of Wisconsin-Madison , Madison, WI
6 shared publications - Francy Cruz-Sanabria
Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, via Savi 10, 56126, Pisa, Italy
3 shared publications - Marta Mosca
Rheumatology Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa , Pisa
3 shared publications Paolo Frumento
Department of Political Sciences, University of Pisa, Via Filippo Serafini 3, 56126, Pisa, Italy
3 shared publications- Paolo Frumento
Department of Political Sciences, University of Pisa , Pisa
3 shared publications
Latest Publications
- 10 September 2026
- Published by Elsevier in Sleep Health
Interpreting insomnia symptoms in evening types requires a precision medicine approach
- 10 September 2026
- Published by Elsevier in Sleep Health
Interpreting insomnia symptoms in evening types requires a precision medicine approach
- Open Access
- 27 July 2026
- Published by Elsevier in SSRN Electronic Journal
Actigraphy-Based Assessment of Primary Sleep Disorders: A Systematic Review and Meta-Analysis
Background: Actigraphy is a wearable accelerometry method widely used in sleep research and clinical practice, yet its diagnostic and phenotypic value remains uncertain due to methodological heterogeneity and inconsistent reporting. This systematic review and meta-analysis determined whether actigraphy-derived metrics distinguish primary sleep disorders from healthy controls, and characterised reporting and methodological practices.Methods: Electronic databases were searched for observational studies published in 1990–2025 using actigraphy in patients with insomnia disorder (ID), central disorders of hypersomnolence (CDH), or circadian rhythm sleep–wake disorders (CRSWD), alongside healthy controls. Standardised mean differences (Hedges' g) were pooled using random-effects models. This study is registered with PROSPERO (CRD420251231134).Findings: 37 studies met eligibility criteria, of which 34 contributed to the meta-analysis. The sample comprised 1517 patients with ID, 105 with narcolepsy type 1 (NT1), 110 with delayed sleep–wake phase disorder (DSWPD), and 1647 healthy controls; no studies were identified for other CDH or CRSWD subtypes. In ID, actigraphy showed prolonged sleep onset latency (0·53 [95% CI 0·40–0·66]), reduced sleep efficiency (−0·65 [−0·83 to −0·47]), and increased wake after sleep onset (0·55 [0·34–0·75]). In NT1, nocturnal disruption was more severe (sleep efficiency −1·77 [−2·63 to −0·90]; wake after sleep onset 1·83 [1·09–2·56]), with reduced daytime activity (−0·90 [−1·19 to −0·61]) and increased napping. In DSWPD, sleep onset time (2·10 [1·56–2·63]) and offset time (1·45 [0·96–1·94]) were delayed, with modestly reduced total sleep time but preserved sleep efficiency. Heterogeneity was moderate-to-high for most estimates. Reporting concentrated on nocturnal continuity parameters, while diurnal and night-to-night variability metrics remained underrepresented. Devices, algorithms, and acquisition protocols varied substantially.Interpretation: Actigraphy identified disorder-specific signatures: impaired sleep continuity in ID, nocturnal disruption with daytime impairment in NT1, and delayed timing with preserved sleep efficiency in DSWPD, supporting pathophysiology-aligned metric selection. Standardised reporting and acquisition protocols are needed to advance clinical translation.
- 27 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessActigraphy-Based Assessment of Primary Sleep Disorders: A Systematic Review and Meta-Analysis
Background: Actigraphy is a wearable accelerometry method widely used in sleep research and clinical practice, yet its diagnostic and phenotypic value remains uncertain due to methodological heterogeneity and inconsistent reporting. This systematic review and meta-analysis determined whether actigraphy-derived metrics distinguish primary sleep disorders from healthy controls, and characterised reporting and methodological practices.Methods: Electronic databases were searched for observational studies published in 1990–2025 using actigraphy in patients with insomnia disorder (ID), central disorders of hypersomnolence (CDH), or circadian rhythm sleep–wake disorders (CRSWD), alongside healthy controls. Standardised mean differences (Hedges' g) were pooled using random-effects models. This study is registered with PROSPERO (CRD420251231134).Findings: 37 studies met eligibility criteria, of which 34 contributed to the meta-analysis. The sample comprised 1517 patients with ID, 105 with narcolepsy type 1 (NT1), 110 with delayed sleep–wake phase disorder (DSWPD), and 1647 healthy controls; no studies were identified for other CDH or CRSWD subtypes. In ID, actigraphy showed prolonged sleep onset latency (0·53 [95% CI 0·40–0·66]), reduced sleep efficiency (−0·65 [−0·83 to −0·47]), and increased wake after sleep onset (0·55 [0·34–0·75]). In NT1, nocturnal disruption was more severe (sleep efficiency −1·77 [−2·63 to −0·90]; wake after sleep onset 1·83 [1·09–2·56]), with reduced daytime activity (−0·90 [−1·19 to −0·61]) and increased napping. In DSWPD, sleep onset time (2·10 [1·56–2·63]) and offset time (1·45 [0·96–1·94]) were delayed, with modestly reduced total sleep time but preserved sleep efficiency. Heterogeneity was moderate-to-high for most estimates. Reporting concentrated on nocturnal continuity parameters, while diurnal and night-to-night variability metrics remained underrepresented. Devices, algorithms, and acquisition protocols varied substantially.Interpretation: Actigraphy identified disorder-specific signatures: impaired sleep continuity in ID, nocturnal disruption with daytime impairment in NT1, and delayed timing with preserved sleep efficiency in DSWPD, supporting pathophysiology-aligned metric selection. Standardised reporting and acquisition protocols are needed to advance clinical translation.
- 8 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 613
Plasma phosphorylated tau and cerebrovascular burden predict emergency department use in dependent older patients
Background Dependent older patients show high risk of adverse health outcomes when admitted to the emergency department (ED). The prompt identification of ED use risk factors in such population is hence needed. While frailty and cognitive impairment are a known clinical risk factors, biomarkers of most prevalent dementias have been scarcely investigated as possible ED use predictors. Within this framework, this prospective study explored whether plasma phospho-tau181 (ptau181) and cerebrovascular burden provide additional predictive value for 6-month ED use in elderly dependent patients, beyond frailty and age. Methods We collected baseline clinical and laboratory data to validate a 32-item frailty index, while assessing cognitive impairment through the Mini-Mental State Examination. Biomarkers of cognitive impairment included plasma ptau181 and cerebrovascular burden, i.e., the Fazekas Scale. Binomial and Cox regression models tested the biomarkers of cognitive impairment as predictors of ED use, adjusting for frailty and age. The interaction between cognitive impairment biomarkers was explored. Results Of the 102 recruited patients, 38 visited the ED. In the binomial models, the frailty index (OR = 1.69, p = 0.011) and the Fazekas Scale (OR = 3.57, p = 0.007) predicted ED use. At lower p-tau181 levels, ED admission risk increased only with higher cerebrovascular burden. Conversely, higher p-tau181 levels predicted ED use (OR = 4.90, p = 0.037) irrespective of cerebrovascular burden. No significant predictors of time to ED use emerged. Discussion Beyond measures of clinical frailty, the routinary employment of cognitive impairment biomarkers may contribute identifying dependent older patients at short-term high risk of ED use, possibly reducing adverse health outcomes in such population. Graphical Abstract
- 8 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 613
Plasma phosphorylated tau and cerebrovascular burden predict emergency department use in dependent older patients
Background Dependent older patients show high risk of adverse health outcomes when admitted to the emergency department (ED). The prompt identification of ED use risk factors in such population is hence needed. While frailty and cognitive impairment are a known clinical risk factors, biomarkers of most prevalent dementias have been scarcely investigated as possible ED use predictors. Within this framework, this prospective study explored whether plasma phospho-tau181 (ptau181) and cerebrovascular burden provide additional predictive value for 6-month ED use in elderly dependent patients, beyond frailty and age. Methods We collected baseline clinical and laboratory data to validate a 32-item frailty index, while assessing cognitive impairment through the Mini-Mental State Examination. Biomarkers of cognitive impairment included plasma ptau181 and cerebrovascular burden, i.e., the Fazekas Scale. Binomial and Cox regression models tested the biomarkers of cognitive impairment as predictors of ED use, adjusting for frailty and age. The interaction between cognitive impairment biomarkers was explored. Results Of the 102 recruited patients, 38 visited the ED. In the binomial models, the frailty index (OR = 1.69, p = 0.011) and the Fazekas Scale (OR = 3.57, p = 0.007) predicted ED use. At lower p-tau181 levels, ED admission risk increased only with higher cerebrovascular burden. Conversely, higher p-tau181 levels predicted ED use (OR = 4.90, p = 0.037) irrespective of cerebrovascular burden. No significant predictors of time to ED use emerged. Discussion Beyond measures of clinical frailty, the routinary employment of cognitive impairment biomarkers may contribute identifying dependent older patients at short-term high risk of ED use, possibly reducing adverse health outcomes in such population. Graphical Abstract
- Open Access
Heart Rate Circadian Oscillations as Digital Biomarkers of Cardiometabolic Health Determinants
AIMS: Cardiometabolic risk factors may impair health by altering the autonomic modulation of the cardiovascular system, a physiological process described by heart rate (HR) circadian oscillations. However, the impact of cardiometabolic health determinants on HR circadian oscillations remains scarcely characterized in real-world, population-based settings. To address this, we applied digital health technologies to investigate how cardiometabolic health determinants shape HR circadian oscillations in a real-world cohort of individuals free of cardiometabolic diseases. METHODS: First, a 10-fold cross-validation of a model was performed, aiming at mitigating wearables’ measurement error caused by motion artifacts. This process was informed by 10,056 epochs of concurrent wearable-derived and polysomnographic HR assessment, yielding an average 1.3 bpm reduction in wearables measurement error. We subsequently applied this model to over 2 million 1-minute epochs of HR data, derived from 7-day continuous actigraphic recordings of 245 individuals free of cardiometabolic disorders. Functional-on-scalar regression modelling and both parametric and nonparametric analyses characterized HR circadian profiles and their relationships with demographics, lifestyle, chronotype, sleep health, and chronic insomnia diagnosis. A 6-dimension sleep health index was calculated. RESULTS: Sex, chronotype, and sleep health predominantly shaped HR circadian oscillations. In detail, females consistently showed higher HR across the 24 hours. Moreover, chronotype was associated to a phase shift in HR circadian profiles, with later timings corresponding to eveningness. Notably, sleep health impacted HR circadian oscillations in a dose-dependent fashion: each additional impaired sleep dimension was associated with a 1.2 bpm HR increase during nighttime, alongside reduced circadian robustness and delayed oscillation timings. Finally, the earlier occurrence of morning HR peaks served as a digital biomarker of insomnia (80% specificity, 74% sensitivity). CONCLUSIONS: This work provides a digital health framework to characterize HR circadian oscillations in free-living populations and supports its clinical utility in capturing the autonomic disruptions related to cardiometabolic health determinants. GRAPHICAL
Open AccessHeart Rate Circadian Oscillations as Digital Biomarkers of Cardiometabolic Health Determinants
AIMS: Cardiometabolic risk factors may impair health by altering the autonomic modulation of the cardiovascular system, a physiological process described by heart rate (HR) circadian oscillations. However, the impact of cardiometabolic health determinants on HR circadian oscillations remains scarcely characterized in real-world, population-based settings. To address this, we applied digital health technologies to investigate how cardiometabolic health determinants shape HR circadian oscillations in a real-world cohort of individuals free of cardiometabolic diseases. METHODS: First, a 10-fold cross-validation of a model was performed, aiming at mitigating wearables’ measurement error caused by motion artifacts. This process was informed by 10,056 epochs of concurrent wearable-derived and polysomnographic HR assessment, yielding an average 1.3 bpm reduction in wearables measurement error. We subsequently applied this model to over 2 million 1-minute epochs of HR data, derived from 7-day continuous actigraphic recordings of 245 individuals free of cardiometabolic disorders. Functional-on-scalar regression modelling and both parametric and nonparametric analyses characterized HR circadian profiles and their relationships with demographics, lifestyle, chronotype, sleep health, and chronic insomnia diagnosis. A 6-dimension sleep health index was calculated. RESULTS: Sex, chronotype, and sleep health predominantly shaped HR circadian oscillations. In detail, females consistently showed higher HR across the 24 hours. Moreover, chronotype was associated to a phase shift in HR circadian profiles, with later timings corresponding to eveningness. Notably, sleep health impacted HR circadian oscillations in a dose-dependent fashion: each additional impaired sleep dimension was associated with a 1.2 bpm HR increase during nighttime, alongside reduced circadian robustness and delayed oscillation timings. Finally, the earlier occurrence of morning HR peaks served as a digital biomarker of insomnia (80% specificity, 74% sensitivity). CONCLUSIONS: This work provides a digital health framework to characterize HR circadian oscillations in free-living populations and supports its clinical utility in capturing the autonomic disruptions related to cardiometabolic health determinants. GRAPHICAL
- Open Access
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Exploring sleep health and circadian rhythm disruption in Sjögren’s disease: an accelerometric and self-reported cross-sectional study
In a cross-sectional study, we aimed at characterizing possible impairments in sleep health and rest–activity parameters between patients with Sjögren’s Disease (SjD) and healthy controls (HCs). Furthermore, we explored possible predictors of such disturbances in the SjD group. Participants’ sleep and rest-activity rhythms were assessed via 7-day continuous accelerometry, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, and the reduced Morningness-Eveningness Questionnaire, allowing the creation of a multidimensional sleep health index. Parametric tests explored between-group differences in sleep and rest-activity parameters, while functional linear modelling characterized between-group, time-related differences in accelerometric activity. Within the SjD cohort, regression analysis was employed to explore disease activity, patient-reported disease burden, and the Hospital Anxiety and Depression Scale (HADS) as possible predictors of sleep and rest-activity parameters. Forty-six SjD patients and forty age-, sex- and BMI-matched HCs were included. Compared with HCs, SjD patients reported lower sleep health (p= 0.005) and delayed mid-sleep point (p= 0.009) and acrophase (p= 0.033). Functional linear modelling confirmed the objective shift towards eveningness in SjD patients. In SjD patients, patient-reported disease burden predicted sleep quality (β = 0.41; p= 0.044) and sleepiness (β = 0.83; p= 0.010), while disease activity predicted daily steps (β=-526; p= 0.013), total sleep time (β = 0.15; p= 0.0496) and sleep regularity (β=-1.3; p= 0.030). Finally, HADS predicted daily steps (β=-238; p= 0.041), total sleep time (β=-0.08; p= 0.035) and sleep efficiency (β=-0.65; p= 0.012). SjD is associated with impaired sleep health and rest-activity rhythms. In SjD patients, such alterations differentially associate with disease activity and patient-reported outcomes, supporting a multifactorial model of sleep and circadian rhythms disruption.
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Open AccessExploring sleep health and circadian rhythm disruption in Sjögren’s disease: an accelerometric and self-reported cross-sectional study
In a cross-sectional study, we aimed at characterizing possible impairments in sleep health and rest–activity parameters between patients with Sjögren’s Disease (SjD) and healthy controls (HCs). Furthermore, we explored possible predictors of such disturbances in the SjD group. Participants’ sleep and rest-activity rhythms were assessed via 7-day continuous accelerometry, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, and the reduced Morningness-Eveningness Questionnaire, allowing the creation of a multidimensional sleep health index. Parametric tests explored between-group differences in sleep and rest-activity parameters, while functional linear modelling characterized between-group, time-related differences in accelerometric activity. Within the SjD cohort, regression analysis was employed to explore disease activity, patient-reported disease burden, and the Hospital Anxiety and Depression Scale (HADS) as possible predictors of sleep and rest-activity parameters. Forty-six SjD patients and forty age-, sex- and BMI-matched HCs were included. Compared with HCs, SjD patients reported lower sleep health (p= 0.005) and delayed mid-sleep point (p= 0.009) and acrophase (p= 0.033). Functional linear modelling confirmed the objective shift towards eveningness in SjD patients. In SjD patients, patient-reported disease burden predicted sleep quality (β = 0.41; p= 0.044) and sleepiness (β = 0.83; p= 0.010), while disease activity predicted daily steps (β=-526; p= 0.013), total sleep time (β = 0.15; p= 0.0496) and sleep regularity (β=-1.3; p= 0.030). Finally, HADS predicted daily steps (β=-238; p= 0.041), total sleep time (β=-0.08; p= 0.035) and sleep efficiency (β=-0.65; p= 0.012). SjD is associated with impaired sleep health and rest-activity rhythms. In SjD patients, such alterations differentially associate with disease activity and patient-reported outcomes, supporting a multifactorial model of sleep and circadian rhythms disruption.
- 1 March 2026
- Published by Wiley in Journal of Pineal Research
- Vol. 78 (2)
Navigating Melatonin Safety: Fact, Fiction, and Confounders
As a chronobiotic with sleep‐promoting properties, melatonin is frequently recommended by sleep medicine practitioners and widely available as an over‐the‐counter drug. Recently, two publications questioned melatonin safety profile in insomnia patients, with one of these receiving vast media coverage and noticeable resonance among the general public. This letter to the Editor critically evaluates such research, offering a broader contextualization within the existing body of literature about melatonin safety and insomnia‐related health outcomes.
- 1 March 2026
- Published by Wiley in Journal of Pineal Research
- Vol. 78 (2)
Navigating Melatonin Safety: Fact, Fiction, and Confounders
As a chronobiotic with sleep‐promoting properties, melatonin is frequently recommended by sleep medicine practitioners and widely available as an over‐the‐counter drug. Recently, two publications questioned melatonin safety profile in insomnia patients, with one of these receiving vast media coverage and noticeable resonance among the general public. This letter to the Editor critically evaluates such research, offering a broader contextualization within the existing body of literature about melatonin safety and insomnia‐related health outcomes.
- 21 September 2025
- Published by Wiley in Journal of Pineal Research
- Vol. 77 (5) , e70085
Circadian Misalignment as a Determinant of Insomnia Severity: Possible Implications in Sleep Medicine Clinical Practice
In this letter to the editor, we comment on the recently published study from Scott et al. (2025), which highlights circadian misalignment as a possible determinant of insomnia severity. Considering the robust methodology of this study and in light of recent research aiming at optimizing melatonin treatment schedules, our letter explores why these findings may pave the way towards an extension of current recommendations for melatonin administration in insomnia, while encouraging the quantification of circadian misalignment during sleep medicine clinical practice. Finally, possible methodologies to routinely assess circadian misalignment in insomnia patients are discussed.
- 21 September 2025
- Published by Wiley in Journal of Pineal Research
- Vol. 77 (5) , e70085
Circadian Misalignment as a Determinant of Insomnia Severity: Possible Implications in Sleep Medicine Clinical Practice
In this letter to the editor, we comment on the recently published study from Scott et al. (2025), which highlights circadian misalignment as a possible determinant of insomnia severity. Considering the robust methodology of this study and in light of recent research aiming at optimizing melatonin treatment schedules, our letter explores why these findings may pave the way towards an extension of current recommendations for melatonin administration in insomnia, while encouraging the quantification of circadian misalignment during sleep medicine clinical practice. Finally, possible methodologies to routinely assess circadian misalignment in insomnia patients are discussed.
- Open Access
- 9 June 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (10) , 5460-5470
Sleep and circadian parameters in Behçet’s syndrome: a comparative analysis using actigraphy and questionnaires
Objective: Sleep disturbances are highly prevalent in Behçet syndrome (BS) patients. Within this population, sleep disturbances are frequently associated with active disease and comorbid fibromyalgia. However, possible sleep impairments in BS patients without these conditions remain poorly explored, along with BS patients’ obstructive sleep apnoea syndrome (OSAS) risk and circadian rhythm preferences. We aimed to address these research gaps through a cross-sectional study comparing sleep and circadian parameters between BS patients, with or without active disease and comorbid fibromyalgia, and healthy controls (HCs). Methods: Participants’ sleep and circadian parameters were evaluated objectively via actigraphy and subjectively through the Pittsburgh Sleep Quality Index and the reduced Morningness–Eveningness Questionnaire. A comprehensive clinical evaluation investigated sociodemographic data, disease activity and comorbid fibromyalgia. Possible predictors of sleep and circadian parameters were tested estimating linear regression models. Results: Forty-five BS patients and 61 age-, BMI-, sex- and smoking habits-matched HCs were enrolled. Only BS patients with active disease and/or fibromyalgia showed significantly lower sleep quality, significantly higher sleep fragmentation and a tendence towards less robust circadian rhythms compared to other participants. Instead, BS patients without those conditions did not significantly differ from HCs in sleep and circadian parameters. Furthermore, a higher actigraphically-determined OSAS risk was found in all BS patients compared to HCs. Conclusions: Active disease and fibromyalgia are associated with sleep and circadian rhythm disturbances in BS patients. Screening for sleep and circadian rhythm disturbances may be advised in BS patients with these conditions, while OSAS screening may be recommended in all BS patients with sleep disturbances.
- 9 June 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (10) , 5460-5470
Open AccessSleep and circadian parameters in Behçet’s syndrome: a comparative analysis using actigraphy and questionnaires
Objective: Sleep disturbances are highly prevalent in Behçet syndrome (BS) patients. Within this population, sleep disturbances are frequently associated with active disease and comorbid fibromyalgia. However, possible sleep impairments in BS patients without these conditions remain poorly explored, along with BS patients’ obstructive sleep apnoea syndrome (OSAS) risk and circadian rhythm preferences. We aimed to address these research gaps through a cross-sectional study comparing sleep and circadian parameters between BS patients, with or without active disease and comorbid fibromyalgia, and healthy controls (HCs). Methods: Participants’ sleep and circadian parameters were evaluated objectively via actigraphy and subjectively through the Pittsburgh Sleep Quality Index and the reduced Morningness–Eveningness Questionnaire. A comprehensive clinical evaluation investigated sociodemographic data, disease activity and comorbid fibromyalgia. Possible predictors of sleep and circadian parameters were tested estimating linear regression models. Results: Forty-five BS patients and 61 age-, BMI-, sex- and smoking habits-matched HCs were enrolled. Only BS patients with active disease and/or fibromyalgia showed significantly lower sleep quality, significantly higher sleep fragmentation and a tendence towards less robust circadian rhythms compared to other participants. Instead, BS patients without those conditions did not significantly differ from HCs in sleep and circadian parameters. Furthermore, a higher actigraphically-determined OSAS risk was found in all BS patients compared to HCs. Conclusions: Active disease and fibromyalgia are associated with sleep and circadian rhythm disturbances in BS patients. Screening for sleep and circadian rhythm disturbances may be advised in BS patients with these conditions, while OSAS screening may be recommended in all BS patients with sleep disturbances.
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4143-4153
Active disease, fibromyalgia and exposure to glucocorticoids differentially associate with sleep and circadian parameters in Behçet’s syndrome
Objective: Sleep disturbances significantly impact Behçet’s syndrome (BS) patients’ quality of life. Defining the correlates of BS patients’ sleep disturbances is needed to improve their management and, in turn, BS patients’ quality of life. In this study, we explored fibromyalgia, disease activity and glucocorticoids exposure as possible predictors of sleep and circadian rhythm parameters in a cohort of BS patients. Methods: Participants’ sociodemographic data were collected through a survey. Sleep and circadian parameters were evaluated objectively via a continuous 7-day accelerometric monitoring and subjectively through the Pittsburgh Sleep Quality Index and the reduced Morningness-Eveningness Questionnaire. A comprehensive clinical evaluation investigated disease activity, fibromyalgia and ongoing pharmacological treatments. Clinical records were systematically reviewed to derive glucocorticoids exposure variables. Possible predictors of sleep and circadian parameters were tested estimating linear regression models. Results: A total of 45 BS patients were enrolled. Both active and fibromyalgic BS patients showed lower reported sleep quality and lower objectively recorded sleep efficiency compared with non-active and non-fibromyalgic BS patients, respectively. Moreover, fibromyalgia was associated with both shorter total sleep time and a more stable day-to-day rest-activity pattern. In parallel, active disease was associated with reduced sleep regularity whereas glucocorticoids exposure was associated with its increase. Conclusion: Fibromyalgia and active disease shape partially diverging sleep and circadian rhythm disruption patterns in BS patients, with glucocorticoids potentially improving BS patients’ sleep regularity by limiting disease activity-related sleep disruption. A multidimensional approach to sleep characterization is needed to better identify the correlates of BS patients’ sleep disturbances and improve their management.
- 14 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4143-4153
Active disease, fibromyalgia and exposure to glucocorticoids differentially associate with sleep and circadian parameters in Behçet’s syndrome
Objective: Sleep disturbances significantly impact Behçet’s syndrome (BS) patients’ quality of life. Defining the correlates of BS patients’ sleep disturbances is needed to improve their management and, in turn, BS patients’ quality of life. In this study, we explored fibromyalgia, disease activity and glucocorticoids exposure as possible predictors of sleep and circadian rhythm parameters in a cohort of BS patients. Methods: Participants’ sociodemographic data were collected through a survey. Sleep and circadian parameters were evaluated objectively via a continuous 7-day accelerometric monitoring and subjectively through the Pittsburgh Sleep Quality Index and the reduced Morningness-Eveningness Questionnaire. A comprehensive clinical evaluation investigated disease activity, fibromyalgia and ongoing pharmacological treatments. Clinical records were systematically reviewed to derive glucocorticoids exposure variables. Possible predictors of sleep and circadian parameters were tested estimating linear regression models. Results: A total of 45 BS patients were enrolled. Both active and fibromyalgic BS patients showed lower reported sleep quality and lower objectively recorded sleep efficiency compared with non-active and non-fibromyalgic BS patients, respectively. Moreover, fibromyalgia was associated with both shorter total sleep time and a more stable day-to-day rest-activity pattern. In parallel, active disease was associated with reduced sleep regularity whereas glucocorticoids exposure was associated with its increase. Conclusion: Fibromyalgia and active disease shape partially diverging sleep and circadian rhythm disruption patterns in BS patients, with glucocorticoids potentially improving BS patients’ sleep regularity by limiting disease activity-related sleep disruption. A multidimensional approach to sleep characterization is needed to better identify the correlates of BS patients’ sleep disturbances and improve their management.
- Open Access
- 28 September 2024
- Published by Elsevier in Sleep Health
- Vol. 10 (6) , 697-704
Chronotype and lifestyle in the transition to adulthood: Exploring the role of sleep health and circadian misalignment
- 28 September 2024
- Published by Elsevier in Sleep Health
- Vol. 10 (6) , 697-704
Open AccessChronotype and lifestyle in the transition to adulthood: Exploring the role of sleep health and circadian misalignment